# An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

> **NCT07589569** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** HRS-7058

## Key facts

- **NCT ID:** NCT07589569
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07589569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07589569, "An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT07589569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*